[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"incontinence-associated-dermatitis\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:incontinence-associated-dermatitis":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,44,68,96],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":29,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":4},"100533071","testing-the-safety-and-efficacy-of-a-novel-barrier-cream-for-the-treatment-of-moisture-associated-skin-damage-100533071",false,"NCT06221046","Testing the Safety and Efficacy of a Novel Barrier Cream for the Treatment of Moisture Associated Skin Damage","Prospective Evaluation of the Safety and Efficacy of an Enhanced Barrier Cream for the Treatment of Moisture Associated Skin Damage","Patients who meet all the below criteria will be eligible for inclusion in the study:\n\n* ≥18 years of age;\n* Clinical diagnosis of incontinence-associated dermatitis resulting from diarrhea and\u002For fecal incontinence;\n* Minimum expected stay in hospital of two weeks;\n* Able to provide written informed consent (OR consent by a recognized substitute-decision maker) including explicit consent to take daily photographs of the rash associated with MASD.\n\nPatients who meet any of the following exclusion criteria will not be eligible for enrolment:\n\n* History of complex skin disorders (such as psoriasis or eczema);\n* Allergy to any of the ingredients in the study product;\n* Visual evidence of a bacterial skin infection;\n* Anticipated length of stay in hospital less than two weeks;\n* Life expectancy less than two weeks;\n* Use of a dressing or bandage covering the rash that cannot reasonably be removed for required study activities without compromising patient comfort or care.\n\nNote: Patients who are pregnant will not be excluded from the study unless they present with a rash or other skin conditions that may confound assessments.","ALL","18 Years",{"count":19,"type":20},60,"ESTIMATED","INTERVENTIONAL",[23],"NA","Liquid stool and diarrhea are associated with an increased risk for moisture-associated skin damage (MASD), and clinical evidence suggests that exposure to liquid stool is associated with severe MASD and extensive erosion of affected skin. There are no known products on the market that treat fecal incontinence or MASD caused by fecal enzyme activity.\n\nScotiaderm has invented a novel barrier cream (Dermategrity \"Anti-fecal\" Barrier Cream) with an enhanced formula containing zinc oxide and a natural plant extract that inhibits fecal enzymes to protect the skin while preventing further breakdown. Dermategrity \"Anti-fecal\" Barrier Cream has shown superior outcomes in comparison to zinc oxide alone in simulated laboratory testing, and promising results have been obtained in clinical case studies. To date, however, there has been no formal clinical testing of this new barrier product in comparison to standard zinc oxide creams.\n\nThe purpose of this study is to perform a randomized, controlled clinical study comparing Dermategrity \"Anti-fecal\" Barrier Cream to zinc oxide barrier cream to determine if there is a difference in healing, clinical outcomes, and the speed of resolution of MASD symptoms between groups.",[26,27,28],"Moisture Associated Skin Damage","Incontinence Associated Dermatitis","Fecal Incontinence",[30,26,27,31,28],"MASD","IAD","NOT_YET_RECRUITING","2026-06-29",{"date":35,"type":36},"2026-07-01","ACTUAL",{"date":38,"type":20},"2026-08-31",{"date":40,"type":20},"2027-08-01",{"name":42,"class":43},"Scotiaderm","OTHER",{"id":45,"slug":46,"hasResults":11,"nctId":47,"briefTitle":48,"officialTitle":49,"acronym":4,"eligibilityCriteria":50,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":51,"targetDuration":4,"studyType":21,"phases":53,"briefSummary":54,"conditions":55,"keywords":56,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":59,"lastUpdatePostDateStruct":60,"startDateStruct":62,"completionDateStruct":64,"leadSponsor":66,"locationsCount":67},"100544573","testing-a-novel-barrier-cream-for-fecal-incontinence-in-an-ambulatory-population-100544573","NCT06370637","Testing a Novel Barrier Cream for Fecal Incontinence in an Ambulatory Population","Comparison of an Enhanced Barrier Cream to Standard of Care for the Treatment of Moisture Associated Skin Damage From Fecal Incontinence in an Ambulatory Population","Inclusion Criteria\n\n* ≥18 years of age\n* Clinical diagnosis of incontinence-associated dermatitis resulting from diarrhea and\u002For fecal incontinence.\n* Able to provide written informed consent\n* Either able to self-administer barrier cream to the affected region OR administer with the assistance of a caregiver\n\nExclusion Criteria\n\n* History of complex skin disorders (such as psoriasis or eczema)\n* Known allergy to any of the ingredients in the study product\n* Visual evidence of a bacterial skin infection\n* Use of a dressing or bandage covering the rash that cannot reasonably be removed for required study activities without compromising patient comfort or care.\n* Patients who are pregnant will not be excluded from the study unless they present with a rash or other skin conditions that may confound assessments\n* A medical condition that, in the opinion of the investigator, precludes the patient from being able to provide informed consent OR presents confounds which may bias the study outcomes",{"count":52,"type":20},40,[23],"Liquid stool and diarrhea are associated with an increased risk for moisture-associated skin damage (MASD), and clinical evidence suggests that exposure to liquid stool is associated with severe MASD and extensive erosion of affected skin. There are no known products on the market that treat fecal incontinence or MASD caused by fecal enzyme activity.\n\nScotiaderm has invented a novel barrier cream (Dermategrity Everyday Barrier Cream) with an enhanced formula containing zinc oxide and a natural plant extract that inhibits fecal enzymes to protect the skin while preventing further breakdown. Dermategrity Everyday Barrier Cream has shown superior outcomes in comparison to zinc oxide alone in simulated laboratory testing, and promising results have been obtained in clinical case studies. To date, however, there has been no formal clinical testing of this new barrier product in comparison to standard zinc oxide creams.\n\nThe purpose of this study is to perform a randomized, controlled clinical study comparing Dermategrity Everyday Barrier Cream to zinc oxide barrier cream to determine if there is a difference in healing, clinical outcomes, and the speed of resolution of MASD symptoms between groups, in an ambulatory patient population.",[26,28,27],[30,26,31,27,28,57,58],"Dermategrity","Barrier Cream","2026-06-22",{"date":61,"type":36},"2026-06-25",{"date":63,"type":20},"2026-09-01",{"date":65,"type":20},"2027-11-01",{"name":42,"class":43},1,{"id":69,"slug":70,"hasResults":11,"nctId":71,"briefTitle":72,"officialTitle":73,"acronym":74,"eligibilityCriteria":75,"healthyVolunteers":76,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":77,"targetDuration":4,"studyType":21,"phases":79,"briefSummary":80,"conditions":81,"keywords":83,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":87,"lastUpdatePostDateStruct":88,"startDateStruct":90,"completionDateStruct":92,"leadSponsor":94,"locationsCount":4},"100565580","prevention-of-incontinence-associated-dermatitis-and-maintenance-of-local-skin-microclimatea-multicenter-study-100565580","NCT06644027","Prevention of Incontinence-associated Dermatitis and Maintenance of Local Skin Microclimate：A Multicenter Study","Effect of Different Types of Disposable Absorbent Sheets on the Local Skin Microclimate and Incidence of Incontinence-associated Dermatitis in Patients With Incontinence in the ICU: a Multicenter Randomized Controlled Trial","I-and-M-m","Inclusion Criteria:\n\n1. Intensive care unit incontinent patients (incontinence time ≥2 days)\n2. Age ≥18 years\n3. patients at high risk of IAD (Perineal Assessment Tool ≥ 7)\n4. Voluntarily participate in the study and sign an informed consent form. If the subject is unable to read and sign the informed consent form due to incapacitation or other reasons, their guardian is required to represent the informed process and sign the informed consent form. If the subject is unable to read the informed consent form (e.g., illiterate subjects), a witness will be required to witness the informed process and sign the informed consent form.\n\nExclusion Criteria:\n\n1. Patients who have developed IAD\n2. Expected subsequent stay in the intensive care unit \\\u003C5 days\n3. Use of nappies, pull-ups, incontinence pads, etc.\n4. Simple urinary incontinence with indwelling catheterization, external urinary bag without leakage; simple fecal incontinence with built-in drainage device, external ostomy bag, OB tampon without leakage; double incontinence with indwelling catheterization, external urinary bag, built-in drainage device, external ostomy bag, OB tampon without leakage.\n5. The IAD may affect the skin area within the scope of the disease that affects the IAD judgment.\n6. The IAD may affect the skin area within the scope of the skin breaks, infection\n7. Patients who are not suitable for turning and cannot tolerate the side-lying position.\n8. Patients with known allergies or keloid scarring\n9. Women who are known to be pregnant or breastfeeding or who are planning to have a baby during the study period.\n10. Patients who have participated in a clinical trial of another drug or medical device within 3 months.\n11. Patients who, in the opinion of the investigator, are not suitable for participation in this clinical trial.",true,{"count":78,"type":20},125,[23],"To explore the feasibility of Jefcare Sterile Medical Sheets in preventing incontinence-associated dermatitis and maintaining a stable local skin microclimate in adult patients in the intensive care unit.",[82],"Incontinence-associated Dermatitis",[84,85,86],"incontinence-associated dermatitis","microclimate","Jefcare Sterile Medical Sheets","2024-10-13",{"date":89,"type":36},"2024-10-16",{"date":91,"type":20},"2024-10-10",{"date":93,"type":20},"2025-04-10",{"name":95,"class":43},"Sir Run Run Shaw Hospital",{"id":97,"slug":98,"hasResults":11,"nctId":99,"briefTitle":100,"officialTitle":101,"acronym":4,"eligibilityCriteria":102,"healthyVolunteers":11,"sex":103,"minAge":104,"maxAge":4,"enrollmentInfo":105,"targetDuration":4,"studyType":21,"phases":106,"briefSummary":107,"conditions":108,"keywords":4,"overallStatus":112,"whyStopped":4,"lastUpdateSubmitDate":113,"lastUpdatePostDateStruct":114,"startDateStruct":116,"completionDateStruct":118,"leadSponsor":120,"locationsCount":67},"100563233","effectiveness-of-the-ai-supporter-in-reducing-urinary-tract-infections-100563233","NCT06613503","Effectiveness of the AI-Supporter in Reducing Urinary Tract Infections","Testing the Effectiveness of the AI-Supporter in Reducing Urinary Tract Infections, Incontinence-associated Dermatitis and Caregiving Costs for Incontinence Patients","Inclusion Criteria:\n\n* Participants must have been bedridden for at least 3 months and have urinary and\u002For fecal incontinence.\n* Female participants aged over 20 years old.\n* Participants must be capable of wearing the AI-supporter device during the study period.\n\nExclusion Criteria:\n\n* Participants with severe skin conditions unrelated to incontinence.\n* Participants with current urinary tract infections or incontinence-associated dermatitis at the time of enrollment.\n* Participants who are unable to provide informed consent or have a legal representative to do so.","FEMALE","20 Years",{"count":19,"type":20},[23],"The \"AI Supporter,\" an intelligent excretion management robot, leverages artificial intelligence-based vision recognition to autonomously detect and cleanse affected areas, followed by drying and changing the diaper, thereby reducing caregiver strain and enhancing care quality. This study aims to assess the efficacy of the \"AI Supporter\" in decreasing the incidence of urinary tract infections and incontinence-associated dermatitis among incontinent patients, in addition to exploring its cost-effectiveness.\n\nAdopting an experimental (two groups) and longitudinal design, this research utilizes both convenience and random sampling strategies. The study anticipates recruiting 60 female subjects who have been confined to bed for more than three months with urinary and\u002For fecal incontinence. Participants will intermittently use the AI Supporter over a 14-day period. Measurement tools include routine urine analysis.",[109,110,82,111],"Incontinence","Urinary Tract Infection","Cost-effectiveness","RECRUITING","2024-09-23",{"date":115,"type":36},"2024-09-26",{"date":117,"type":36},"2024-07-22",{"date":119,"type":20},"2025-10-31",{"name":121,"class":43},"China Medical University Hospital"]